165 related articles for article (PubMed ID: 16119218)
1. Engineering genomics. RNA antagonists--a new class of antisense drugs.
Orum H
IEEE Eng Med Biol Mag; 2005; 24(4):81-7. PubMed ID: 16119218
[No Abstract] [Full Text] [Related]
2. [Application of functional RNAs in human diseases].
Tanaka Y; Kozu T
Tanpakushitsu Kakusan Koso; 2006 Nov; 51(14 Suppl):2235-7. PubMed ID: 17471945
[No Abstract] [Full Text] [Related]
3. The diversity of RNAi and its applications.
Gaur RK; Rossi JJ
Biotechniques; 2006 Apr; Suppl():4-5. PubMed ID: 16629381
[No Abstract] [Full Text] [Related]
4. RNA-based drugs: from RNA interference to short interfering RNAs.
Poliseno L; Mercatanti A; Citti L; Rainaldi G
Curr Pharm Biotechnol; 2004 Aug; 5(4):361-8. PubMed ID: 15320767
[TBL] [Abstract][Full Text] [Related]
5. Mammalian RNAi: a practical guide.
Sandy P; Ventura A; Jacks T
Biotechniques; 2005 Aug; 39(2):215-24. PubMed ID: 16116795
[TBL] [Abstract][Full Text] [Related]
6. RNA interference: a potential therapeutic tool for silencing splice isoforms linked to human diseases.
Gaur RK
Biotechniques; 2006 Apr; Suppl():15-22. PubMed ID: 16629383
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of RNAi in metabolic diseases.
Rondinone CM
Biotechniques; 2006 Apr; Suppl():31-6. PubMed ID: 16629385
[TBL] [Abstract][Full Text] [Related]
8. Toward silencing the burden of malaria: progress and prospects for RNAi-based approaches.
Brown AE; Catteruccia F
Biotechniques; 2006 Apr; Suppl():38-44. PubMed ID: 16629386
[TBL] [Abstract][Full Text] [Related]
9. Target selectivity in mRNA silencing.
Aronin N
Gene Ther; 2006 Mar; 13(6):509-16. PubMed ID: 16520821
[TBL] [Abstract][Full Text] [Related]
10. Current prospects for RNA interference-based therapies.
Davidson BL; McCray PB
Nat Rev Genet; 2011 May; 12(5):329-40. PubMed ID: 21499294
[TBL] [Abstract][Full Text] [Related]
11. CRISPR genome-editing: A medical revolution.
Butler JR; Tector AJ
J Thorac Cardiovasc Surg; 2017 Feb; 153(2):488-491. PubMed ID: 28104200
[No Abstract] [Full Text] [Related]
12. Cardiovascular pharmacogenomics.
Johnson JA; Cavallari LH
Exp Physiol; 2005 May; 90(3):283-9. PubMed ID: 15778411
[TBL] [Abstract][Full Text] [Related]
13. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?
Rayburn ER; Zhang R
Drug Discov Today; 2008 Jun; 13(11-12):513-21. PubMed ID: 18549978
[TBL] [Abstract][Full Text] [Related]
14. The potential of oligonucleotides for therapeutic applications.
Fichou Y; Férec C
Trends Biotechnol; 2006 Dec; 24(12):563-70. PubMed ID: 17045686
[TBL] [Abstract][Full Text] [Related]
15. Dicing with siRNA.
Williams BR
Nat Biotechnol; 2005 Feb; 23(2):181-2. PubMed ID: 15696144
[No Abstract] [Full Text] [Related]
16. Targeting the human genome.
Tachikawa K; Briggs SP
Curr Opin Biotechnol; 2006 Dec; 17(6):659-65. PubMed ID: 17085035
[TBL] [Abstract][Full Text] [Related]
17. Combining RNA interference with PTD-fusion transcription factors: a novel integrated strategy for achieving trans-differentiation of adult stem cells?
Cao T; Liu H; Heng BC
Med Hypotheses; 2005; 65(5):992-3. PubMed ID: 16002227
[No Abstract] [Full Text] [Related]
18. Switching parasite proteins on and off.
Striepen B
Nat Methods; 2007 Dec; 4(12):999-1000. PubMed ID: 18049467
[No Abstract] [Full Text] [Related]
19. RNA complementary to the 5' UTR of mRNA triggers effective silencing in Saccharomyces cerevisiae.
Bonoli M; Graziola M; Poggi V; Hochkoeppler A
Biochem Biophys Res Commun; 2006 Jan; 339(4):1224-31. PubMed ID: 16343443
[TBL] [Abstract][Full Text] [Related]
20. Research tool with therapeutic potential.
Lederman L
Biotechniques; 2007 Aug; 43(2):155, 157, 159. PubMed ID: 17824382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
